Myalept 11.3 mg/2.2mL (Metreleptin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 11.3 mg/2.2mL

Myalept 11.3 mg/2.2mL is a metreleptin injection used for specific medical conditions. This lyophilized powder for solution is administered subcutaneously and is manufactured by Chiesi USA, Inc.

Strength

11.3 mg/2.2mL

Pack Size

1 VIAL, GLASS in 1 CARTON (10122-210-02) / 2.2 mL in 1 VIAL, GLASS

Manufacturer / TM Owner

Chiesi USA, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Myalept 11.3 mg/2.2mL is a metreleptin injection designed for subcutaneous use. It is commonly used to manage conditions related to leptin deficiency. Metreleptin, the active ingredient, is a recombinant human leptin analog that plays a role in regulating energy balance and metabolism. This medication is often prescribed for specific medical conditions that require leptin replacement therapy.

Side Effects

Myalept 11.3 mg/2.2mL may cause common effects such as injection site reactions, weight loss, and changes in appetite. Some users may experience fatigue or gastrointestinal issues. It is important to monitor for any adverse reactions and consult a healthcare provider if concerns arise.

Precautions & Warnings

Myalept 11.3 mg/2.2mL should be handled with care and stored as directed. It is essential to follow proper administration techniques to avoid contamination or infection. Patients should be aware of potential allergic reactions and seek medical advice if severe side effects occur.

Avoid Interactions

Myalept 11.3 mg/2.2mL may interact with other medications, including those that affect metabolism or immune function. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also influence the effectiveness of metreleptin.

Frequently Asked Questions

Myalept 11.3 mg/2.2mL is used to manage conditions related to leptin deficiency, often involving subcutaneous administration.

Myalept 11.3 mg/2.2mL should be stored according to the manufacturer's instructions to maintain its efficacy.

Common side effects may include injection site reactions, weight loss, and changes in appetite.

It is important to consult a healthcare provider before using Myalept 11.3 mg/2.2mL with other medications to avoid potential interactions.

Myalept 11.3 mg/2.2mL is administered subcutaneously after reconstitution of the lyophilized powder.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.